EGFR and non-small cell lung carcinoma: The exploratory analysis in the EGFR mutation population suggested that patients with EGFR-sensitive mutations or NSCLC treated with tyrosine kinase inhibitors can benefit from the ABCP regimen, adding a new treatment option for this patient population.